ZYMERON CORPORATION

Zymeron Corporation specializes in advanced medical research and development focused on battlefield health threats and acute radiation countermeasures, leveraging expertise in physical and engineering sciences to design rapid diagnostic tools and protective therapeutics. The company develops novel biomedical devices and pharmacological interventions for trauma-induced infections, hemorrhagic shock, and hematopoietic acute radiation syndrome, with a strong emphasis on field-deployable solutions for military medical applications. Their technical capabilities span translational biomedical engineering, infectious disease diagnostics, radioprotective agent formulation, and rapid prototyping of point-of-care medical systems, demonstrating a proven ability to transition laboratory innovations into operational readiness for high-stakes environments. Zymeron’s primary client is the Department of Defense, particularly through the Defense Health Agency, where they deliver SBIR and STTR-funded medical R&D contracts focused on combat casualty care and expeditionary medicine. Their work with DoD centers on developing countermeasures for battlefield injuries, indicating a deep understanding of military medical requirements and a track record of successful Phase I and Phase II SBIR/STTR execution. They have also engaged with the Department of Health and Human Services on biotechnology research initiatives, suggesting cross-agency credibility in advancing public health technologies. The contractor’s core focus lies in NAICS 541715, which encompasses applied research in life sciences excluding nanotechnology and biotechnology, positioning them squarely in the domain of medical device and pharmaceutical development for defense and emergency response. Their niche is the intersection of trauma medicine, infectious disease control, and radiation biology, serving a specialized segment of the federal biomedical R&D market. Zymeron Corporation is a small business structured as a 2L entity, headquartered in Durham, North Carolina. While they hold no formal government certifications, their consistent award history with DoD SBIR/STTR programs underscores their eligibility and competitiveness within the federal small business innovation ecosystem. Their geographic location places them within a major biomedical research corridor, enhancing collaboration potential with academic and clinical partners.